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Murine norovirus (MNoV) is closely related to human norovirus
(HNoV), an infectious agent responsible for acute gastroenteritis
worldwide. Here we report the X-ray crystal structure of the dimeric
MNoV VP1 protruding (P) domain in complex with its cellular receptor
CD300lf. CD300lf binds the P domain with a 2:2 stoichiometry,
engaging a cleft between the AB and DE loops of the P2 subdomain
at a site that overlaps the epitopes of neutralizing antibodies. We also
identify that bile acids are cofactors enhancing MNoV cell-binding and
infectivity. Structures of CD300lf–P domain in complex with glycoche-
nodeoxycholic acid (GCDCA) and lithocholic acid (LCA) reveal two bile
acid binding sites at the P domain dimer interface distant from receptor
binding sites. The structural determinants for receptor and bile acid
binding are supported by numerous biophysical assays utilizing inter-
face residue mutations. We find that the monomeric affinity of CD300lf
for the P domain is low and is divalent cation dependent. We have also
determined the crystal structure of CD300lf in complex with phospho-
choline, revealing that MNoV engages its receptor in a manner mim-
icking host ligands including similar metal coordination. Docking of the
cocomplex structures onto a cryo-EM–derivedmodel of MNoV suggests
that each virion can make multiple CD300lf engagements, and thus,
infection may be driven by the avidity of cell surface clustered CD300lf.
These studies identify multiple potential modulators of norovirus in-
fection that may act to regulate the interaction between the viral cap-
sid P domain and its cognate cellular receptor.
norovirus | virus receptor | bile acid | crystallography
Murine norovirus (MNoV) and human noroviruses (HNoVs)share biological similarities including genome structure,
environmental stability, fecal–oral transmission, replication in
the gastrointestinal tract, and prolonged viral shedding (1).
MNoV is an important model system for noroviruses in part
because it is the only member of the norovirus genus that can be
efficiently cultured, has a reverse genetics system, and can be
studied in a robust small animal model (1–4). Recently, we
identified CD300lf as a proteinaceous cellular receptor for MNoV
essential for MNoV binding and entry in cell lines, primary cells and
mice (5). CD300lf is a critical determinant of MNoV species and
cell tropism (5–7). The CD300 family contains type I trans-
membrane proteins with single Ig-V–like domains involved in im-
munoregulatory processes (8, 9). A general feature of this family
appears to be the ability to bind lipids in a cleft on the extracellular
Ig domain (10). Potential ligands for murine CD300lf include
ceramide, phosphotidylserine, and phosphotidylcholine, with these
ligands binding in a calcium-dependent manner (11–13).
Norovirus is a genus in the Caliciviridae family composed of
nonenveloped positive-sense single-stranded RNA viruses (14).
Caliciviruses are unique among animal viruses in possessing a
capsid composed of a single outward-facing structural protein
called VP1 (15, 16). The capsid consists of 180 VP1 molecules
paired into 90 dimers that self-assemble to form a T = 3 ico-
sahedral shell with a diameter of 35–39 nm. The first 225
N-terminal residues of VP1 encode the shell (S) domain, the
interior surface of the capsid surrounding the viral RNA. The S
domain is highly conserved and consists of an eight-stranded anti-
parallel β-sandwich with two α-helical decorations. The remainder of
the VP1 protein, called the protruding (P) domain, can be divided into
two subdomains, P1 and P2. The P1 subdomain consists of a single α
helix and eight β strands and is connected to the S domain by a flexible
stalk-like hinge (17). The P2 subdomain appears as an insertion in
P1 (137 amino acids, 278–415) that forms a six-stranded antiparallel
β-barrel–like structure. The P2 subdomain makes up the distal sur-
face of the virion and is a target for neutralizing antibodies (18–29).
We previously reported that efficient binding of MNoV to cells
required a <5-kD serum cofactor resistant to boiling, delipidation,
and proteinase K treatment (5). It was recently found that bile can
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enhance HNoV replication in intestinal enteroids by an unknown
mechanism (30). Bile acids are a diverse set of cholesterol-derived
molecules synthesized by host enzymes in the liver (31). They
consist of a hydrophobic core of carbon rings conjugated to a
hydrophilic side chain, typically glycine or taurine. Bile acids are
secreted into the proximal small intestine as primary bile acids but
can be modified by intestinal bacteria into secondary bile acids.
Bile acids are resorbed in the distal small intestine and colon and
returned to the liver through the portal circulation. Herein we
have undertaken a series of structural and biophysical experiments
with the goal of better understanding the structural basis of NoV–
receptor interactions and bile acid-mediated enhancement of viral
attachment and infection.
Results
Crystal Structure of MNoV P Domain in Complex with Murine CD300lf.
To understand the structural basis of MNoV cell recognition,
we obtained a crystal structure of murine CD300lf bound to
the MNoV strain CW3 P domain at 2.0 Å resolution. Crystals
of the P domain/CD300lf cocomplex were obtained in space
group P212121 (a = 48.71 Å, b = 135.24 Å, c = 139.51 Å), and
the structure was determined by molecular replacement. The
final refined model has an Rwork of 18.5% with an Rfree of 22.5%
(SI Appendix, Table S1). The atomic model spans P domain
residues 229–531, with residues 532–541 missing due to poor
electron density, and the entire CD300lf ectodomain (residues
19–131) with an N-terminal methionine added for protein syn-
thesis. In the asymmetric unit, two CD300lf ectodomains bind to
one P domain dimer with each CD300lf monomer contacting
distantly positioned P2 subdomains (Fig. 1). The location of this
binding site is in agreement with results reported for CD300lf with
MNoV CR10 strain capsid (32). The CDR3 and CC′ loops of
CD300lf (SI Appendix, Fig. S1) protrude deep into a cleft between
the P2 subdomain AB and DE loops (SI Appendix, Fig. S2). The
two P monomers in the CD300lf-bound structure adopt nearly iden-
tical conformations yielding a RMSD difference of only 0.22 Å in
Cα over 303 aligned residues. Twenty-one P2 subdomain resi-
dues fall within the footprint of CD300lf, and most are entirely
conserved in MNoV but not HNoV (SI Appendix, Fig. S2).
The Bile Acid GCDCA Enhances MNoV Binding and Infection and Binds
the P Domain. As reported (5), MNoV binding to BV2 cells in
PBS was enhanced by adding 10% FBS (Fig. 2A). We found that
addition of crude bovine bile acids or the individual bile acid
GCDCA, but not taurocholic acid (TCA) or casein, rescued
MNoV binding to cells (Fig. 2A). This enhanced binding of
MNoV to cells translated to increased infectivity (Fig. 2B). No
significant enhancement was observed with TCA, glycocholic acid,
beta-muricholic acid, cholic acid, or tauroursodeoxycholic acid.
We were unable to assess cofactor activity of chenodeoxycholic
acid or deoxycholic acid due to cytotoxic effects or of lithocholic
acid (LCA) due to insolubility. Of note, divalent cations, calcium
plus magnesium, augmented infection when present during viral
adsorption (Fig. 2B). Histo-blood group antigen (HBGA), which
can bind HNoV, failed to increase infectivity (Fig. 2B). We next
performed isothermal calorimetry (ITC) to assess bile acid binding
to the MNoV P domain. Injection of GCDCA into soluble P
domain yielded an average KD of ∼5.76 ± 1.26 μM for three in-
dependent experiments, with ∼1:1 binding stoichiometry (Fig. 2C
and SI Appendix, Fig. S4). Consistent with the virus attachment
and infectivity assays, TCA, which fails to enhance infection, did
not bind the MNoV P domain (Fig. 2D), supporting the relevance
of the observed binding to viral attachment and infection.
Crystal Structure of P Domain in Complex with Bile Acids. To explore
bile acid enhancement of MNoV infection, we obtained crystals
of GCDCA or LCA bound to the CD300lf–P domain complex
(Fig. 3 and SI Appendix, Fig. S3). We chose LCA in addition to
GCDCA as a secondary bile acid present in the intestine of mice
and humans. The structures were solved by molecular re-
placement. GCDCA-bound crystals belong to space group P212121
(a = 49.11 Å, b = 134.82 Å, c = 139.59 Å), and the final refined
model has an Rwork of 20.9% with an Rfree of 25.7% to 1.95 Å
resolution (SI Appendix, Table S2). Similarly, the LCA-bound
crystals belong to space group P21212 (a = 101.09 Å, b = 152.89 Å,
c = 70.04 Å), and the final refined model has an Rwork of 17.4%
with an Rfree of 20.4% to 1.80 Å resolution (SI Appendix, Table
S2). These structures reveal binding pockets located at the dimer
interface between the P1 and P2 subdomains such that each P
dimer binds two bile acid molecules, a stoichiometry consistent
with our ITC analysis (Fig. 2C).
The GCDCA glycine is buried deep in a hydrophobic binding
pocket where oxygens from the carboxyl terminus form a salt
bridge to amino acids in both chains of the P dimer (Fig. 3C).
This interaction involves Arg392, Arg437, and Trp245. The
GCDCA carbon ring core contacts many hydrophobic residues
lining sides of the pocket (Fig. 3D). Similarly, LCA binds into the
same pocket, albeit not as deeply, with a carboxyl oxygen making
Fig. 1. CD300lf binding site is located in the P2 domain of VP1. Ribbonmodel of
the CD300lf–P domain complex structure with a schematic diagram of key in-
teractions given in Bottom for orientation. The two chains of the P domain dimer
are colored cyan and green. The secondary structure of the P domain is indicated
on the greenmonomer. The receptor protein CD300lf is shown in yellowwith the
secondary structure labeled. The metal ions are shown as silver spheres, and the
metal ions associated with one P domain are marked with arrows.
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a salt bridge to Arg392 but with the carbon ring core sitting in a
different orientation relative to GCDCA (SI Appendix, Fig. S3 B
and D). Thus, the hydrophobic nature of the pocket facilitates
binding of diverse bile acids.
To assess whether residues lining the structurally identified
ligand binding pocket control GCDCA binding, we created
mutant proteins for ITC binding analysis. We chose to produce
three variants (Y250D, R390Y, and R437D), avoiding substitu-
tions predicted to affect the P dimer interface (Fig. 3). Bacteri-
ally produced P domain variants eluted from size exclusion
chromatography similar to the wild-type protein. The Y250D
and R437D variants completely lost the ability to bind GCDCA
(Fig. 3E). Arg437 lies deep in the pocket close to the glycine of
GCDCA, whereas Tyr250 forms one side of the pocket that
supports the hydrophobic backbone of bile acid carbon rings
(Fig. 3C). Mutation R390Y enhanced GCDCA binding by ∼50-
fold (Fig. 3E). The Arg390 side chain makes numerous
GCDCA contacts and adopts distinct rotamers in the GCDCA-
bound, LCA-bound, and empty structures, with its position the
most variable element of the ligand binding pocket (Fig. 3C and
SI Appendix, Fig. S3). Taken together, the loss and gain of
function mutations strongly support the structural definition
of the bile acid binding pocket located at the P domain
dimer interface.
Role of Metal Ions in CD300lf Binding. The addition of magnesium
and calcium increased MNoV infection (Fig. 2B), leading us to
examine the role of divalent cations in virus–receptor interac-
tions. Each CD300lf–P domain cocomplex structure contains
three metal ions per P domain. Two are at the CD300lf–P do-
main interface, whereas a third binds midway between the in-
terface metal location and bile acid pocket, held by residues
Gln438 and Asp440. Crystals of the cocomplex between CD300lf
and the P domain alone and of the cocomplex containing
GCDCA were both grown in 100 mMMgCl2 (Figs. 1, 3A, and 4B).
These structures refine well with magnesium, having geometry,
bond angels, and fit of B factors to the environment of the metal
atoms within acceptable limits as assessed via the CheckMyMetal
server (33). The crystal of the cocomplex between CD300lf and
the P domain containing LCA was grown in 100 mM CaCl2 and
contains six Ca2+ ions located analogously to the Mg2+ in the
other two complexes. In all three complexes a divalent cation
(Ca2+ or Mg2+) situated between the CD300lf protein and the P
domain coordinates three atoms in the CD300lf CDR3 loop
(carbonyl oxygen atoms of Lys94 and Gly96 and a side chain ox-
ygen of Asp98) with a carbonyl oxygen from Asn364 in the DE
loop of the P domain. For the Mg2+-containing structures, a second
divalent cation orients the side chain of P domain Asp366 allowing
it to hydrogen bond across the interface to a backbone nitrogen of
Gly96 in the CDR3 loop. However, in the CD300lf–P domain–LCA
structure, the second Ca2+ at the interface enables the carboxylate
oxygen of P domain Asp366 to coordinate to the CDR3 engaged
Ca2+ by virtue of its longer bond distance capacity compared with
Mg2+ (compare Asp366 in Fig. 4 B and C). The significant struc-
tural role of divalent cations at the receptor binding interface is
consistent with the capacity of high concentrations of these ions to
enhance infection.
MNoV Binds CD300lf as a Molecular Mimic of Phospholipids. Phos-
phatidylcholine (PC) is one of several lipids reported to bind
CD300lf (12). To identify the lipid-binding site on CD300lf, we
obtained cocomplex crystals with the head group of PC belonging
to space group P212121 (a = 32.64 Å, b = 40.06 Å, c = 68.29 Å). The
structure was solved by molecular replacement to 1.35 Å resolution
with an Rwork of 16.8% and an Rfree of 19.2% (SI Appendix, Table
S1). The PC head group binds in a hydrophobic cleft between the
CDR3 and CC′ loops (Fig. 4D) in a prominent protrusion extending
out from the main Ig fold. The bottom of the cleft is composed of a
disulfide bond (Cys36–Cys44) and the side chains of Met100, Tyr34,
Trp89, Gln41, and Arg42, which hold the choline end of the PC.
Fig. 2. The bile acid GCDCA enhances MNoV–receptor interactions and binds the P domain. (A) MNoV was incubated with BV2 cells in PBS without divalent
cations (PBS−/−) on ice. Unbound virus was washed off, and MNoV genomes were enumerated relative to host actin transcripts. Bovine bile and glyco-
chenodeoxycholic acid (GCDCA) but not taurocholic acid (TCA) rescued MNoV binding. (B) MNoV was added to a confluent monolayer of BV2 cells in various
buffer conditions at room temperature. Unbound MNoV was removed, and methylcellulose was overlaid. Infection was determined by plaque-forming units
2 d postbinding. FBS, divalent cations (Ca2+ and Mg2+), bovine bile, and GCDCA rescued infectivity, whereas other bile acids and HBGA did not (one-way
ANOVA; means ± SEM; NS, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). Data in A are pooled from at least two independent ex-
periments each performed in at least triplicate. Data in B are from at least three independent experiments performed in at least duplicate. (C) Isothermal
titration calorimetry measurements were performed in which buffer containing GCDCA was injected into the same buffer containing P domain protein.
Fitting of the binding isotherms yielded an average KD of ∼5.76 ± 1.26 μM for GCDCA and close to 1:1 molar stoichiometry (SI Appendix, Fig. S4). The heat of
dilution was determined to be negligible in separate titrations of GCDCA into buffer alone. (D) Despite being chemically similar, TCA did not enhance in-
fection in tissue culture and did not bind P domain in the ITC assay.
































The backbone amide of Asp98 and side chain nitrogen of Arg42
orient the phosphate end of the head group that coordinates with
a Ca2+ ion held by the CDR3 loop. This orientation would allow
the fatty acid tail of phosphatidylcholine to protrude out of the
binding site away from the CD300lf bearing cell, an orientation
consistent with the role of CD300lf as a lipid receptor (11–13).
Fig. 3. Bile acids bind in a deep pocket on the MNoV P domain. (A) Ribbon diagram of the CD300lf–P domain complex loaded with GCDCA displayed as a ball
and stick model with carbon atoms colored in magenta. The two chains of the P domain dimer are colored and oriented as in Fig. 1. (B) Solvent accessible
surface of the P dimer with GCDCA bound. (C) The two panels show the dimer, opened like a book, to reveal contact residues along the pocket walls. P
domain residues within 4.5 Å of GCDCA have carbon atoms colored white, and their surface contributions are mapped in white on the P domain surface. The
ligand makes a salt bridge from the carboxyl terminus of the Gly side chain to Arg392, Arg437, and Trp245. The carbon ring core of the bile acid makes several
hydrophobic contacts with the pocket. (D) Plot of GCDCA contacts within the pocket. (E) P domain variants Y250D and R437D display a greatly diminished
ability to GCDCA as measured by ITC, whereas the R390Y variant displayed a roughly 50-fold enhancement in binding.
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To understand the relationship between CD300lf interactions
with phospholipids and the P domain, we superimposed the PC
and P domain-bound costructures and compared the contact
footprints of each ligand. Both PC and the P domain engage the
same CD300lf surface cavity located between the CDR3 and CC′
loops (Fig. 4), and both coordinate with a similarly positioned
metal ion. Although PC uses an oxygen from the phosphate
group to engage the CDR3 coordinated metal, the P domain
uses the carbonyl oxygen from Asn364. The choline group of PC
makes extensive contact with the CC′ loop. In the P domain-
bound structures, the side chain of Asn364 interacts with many
of the same CC′ loop residues as PC. It is worth noting that
Asn364 is nearly invariant among reported MNoV sequences (SI
Appendix, Fig. S2). These data clearly provide evidence for viral
mimicry, whereby MNoV chemically mimics phospholipid in
engaging the CD300lf receptor.
The MNoV P Domain Binds CD300lf with Low Affinity. We next
measured the binding affinity of CD300lf for the MNoV P do-
main using soluble recombinant proteins. Analysis of CD300lf
binding to the P domain by surface plasmon resonance (SPR)
over a 21–1,667 μM concentration range yielded a monomeric
binding affinity of KD ∼ 219 μM (Fig. 5A). To ensure that this
weak SPR binding signal was specific, we assessed binding of
CD300 family members previously evaluated for a role in MNoV
infection. Of the nine mouse CD300 family members, only CD300lf
and, to a lesser extent, CD300ld conferred MNoV susceptibility to
human HeLa cells, whereas mouse CD300lh and human CD300f
did not (5). Only the soluble ectodomain of mouse CD300lf, and
not mouse CD300ld or CD300lh, or human CD300f neutralizes
MNoV infectivity (5). We therefore measured binding of these
Fig. 4. CD300lf employs a similar strategy to bind PC and the P domain. (A)
Model showing the orientation of the P2 subdomain relative to CD300lf in the
empty (no bile salt) complex colored as in Fig. 1. (B) Close-up of the empty
CD300lf–P domain complex showing the side chain of Asn364 from the P
domain DE loop binding to CD300lf in a pocket made by the CC′ loop. The
carbonyl oxygen of Asn364 coordinates with a magnesium ion at the binding
interface. A second magnesium ion supports the P domain DE loop, holding it
against the binding pocket, by bridging Asp410 and Asp366. (C) Close-up of
the LCA loaded CD300lf–P domain complex showing a calcium ion at the in-
terface. Here Asp366 completes the octahedral coordination of the interface
calcium ion. (D) Close-up of the CD300lf with PC bound. The PC choline moiety
(blue and green sticks) rests in a hydrophobic pocket, whereas the phosphate
group (red and tan sticks) coordinates with a calcium ion held in place by
atoms from the CD300lf CDR3 loop. CD300lf residues around the pocket are
labeled. The expected position for the fatty acid lipid tail attachment is shown.
The tails are drawn extending from one of the PC phosphate oxygen atoms.
Fig. 5. CD300lf binds the P domain with low affinity. Recombinant soluble
MNoV P domain protein was immobilized onto the surface of a CM5 chip for SPR
analysis. (A) The response to various concentrations of soluble mouse CD300lf is
shown. The binding was specific and saturable yielding a KD = 219 ± 5.66 μM,
representing the mean ± SD from three independent experiments. The data
were analyzed using Biaevaluation 3.1 (GE Healthcare). The equilibrium con-
centration curve values were fitted at steady-state assuming a 1:1 bindingmodel.
(B) Comparison of the P domain binding response against various recombinant
ectodomains at 200 μM concentration. Mouse CD300ld, CD300lh, and human
CD300f show very low binding. In magenta, blue, and cyan are the CRD3, CC′
loop, and CDR1 variants where the mouse residues have been replaced by the
human equivalent residues in those loops. Bars represent the mean response ±
SD from three injections. (C) Model showing where the CDR3, CC′ loop, and
CDR1 variants map onto the P domain surface. (D) Binding affinity measured in
the presence of 1 mM CaCl2 by isothermal titration calorimetry. (Top) The raw
data from titration of CD300lf injected into the P domain. (Bottom) The in-
tegrated heats for each injection versus molar ratio of CD300lf to P domain fit
using a one-site binding model. The KD = 24.51 ±1.72 μM and represents the
average from two independent experiments (SI Appendix, Fig. S5). (E) Addition
of 250 μM GCDCA gave about a twofold increase in binding affinity for an av-
erage KD = 12.04 ± 0.17 μM from two experiments (SI Appendix, Fig. S5).
































proteins to the MNoV P domain using SPR (Fig. 5B). Mouse
CD300lf gave a strong signal for binding to the P domain after
background subtraction, whereas very little binding was observed
for mouse CD300ld or CD300lh or human CD300f. We then
assessed if this interaction involved the receptor and PC-binding
determinants of CD300lf identified in our crystal structures.
CD300lf containing human sequence substitutions of the CC′ or
CDR3 loop fail to support MNoV infection, and the soluble ecto-
domains of these proteins do not neutralize MNoV infection (5).
Similarly, mouse CD300lf containing these human sequences or
CDR3 loop exhibited greatly diminished binding to the P domain
(Fig. 5 B and C). A control substitution, more distal from the
binding cleft in the CDR1 loop, diminished the binding signal by
about half (Fig. 5 B and C). These results verify our direct affinity
measurements for the interaction between the P domain and
CD300lf, and the concordance between viral infection and the
binding assays strengthen the conclusion that our structural studies
are directly related to viral receptor function.
Role of Divalent Cations in P Domain Interactions. The cocomplex
crystal structures contain metal ions: two at each P domain/
CD300lf interface and one on the side of each P domain. The
SPR binding was performed in buffer containing 40 μM EDTA,
which sequesters metal ions. Attempts to add Mg2+ or Ca2+ to
the SPR buffer resulted in elevated background preventing in-
terpretation. This led us to develop an ITC assay for binding of
CD300lf to the P domain in solution. We observed binding of P
domain and CD300lf by ITC in buffer consisting of 1 mM CaCl2,
30 mM Hepes, pH 7.4, and 150 mM NaCl, where CD300lf was
injected into P domain containing solution (Fig. 5D). The signal
was specific for CD300lf binding because injection of CD300lf
into the buffer alone (no P domain) gave no signal (SI Appendix,
Fig. S5). The ITC experiments with Ca2+ yielded an average
binding affinity from two experiments of KDave ∼ 24.51±
1.72 μM, a value ∼10-fold higher than we saw by SPR without
Ca2+, further supporting the conclusion that the P domain–
CD300lf interaction is of low affinity and potentially regulated by
divalent cations. Consistent with this, removal of free calcium by
addition of 0.1 M EGTA to the ITC buffer inhibited CD300lf
binding. Addition of 0.1 M EGTA and 1 mM MgCl2 (to chelate
Ca2+ under conditions of excess Mg2+) gave binding similar to that
obtained in 1 mM CaCl2, yielding a KDave of ∼24.29 ± 3.55 μM
from two experiments (SI Appendix, Fig. S5). This suggested that
both divalent cations could play a role in physiologic receptor
binding. However, it remains unclear whether they act directly at
the protein–protein interface or through stabilization of the P do-
main. The availability of this assay allowed us to demonstrate that
addition of GCDCA at a concentration of 250 μM had a small but
reproducible effect on CD300lf binding, yielding an increase in af-
finity of approximately twofold, for a KDave of ∼12.1 ± 0.17 μM
from two experiments (Fig. 5E and SI Appendix, Fig. S5). Although
the importance of this change is unclear, these data support the
concept that bile acids and divalent cations may regulate P domain:
CD300lf interactions in a combinatorial fashion.
Mapping of P Domain Residues Involved in CD300lf Interactions. To
enhance the avidity of binding and to allow mutational studies of
the P domain:CD300lf interface, the CD300lf ectodomain was
joined to a human Fc fragment (Fc–CD300lf), and the protein
was transiently expressed in HEK293 cells. We confirmed the
bivalent Fc–CD300lf fusion protein could recognize the P do-
main using biolayer interferometry (BLI). For this assay,
streptavidin-coated biosensor pins loaded with biotin-labeled
recombinant P domain were tested against wells containing
various concentrations of Fc–CD300lf. Analysis of the response
curves yielded an apparent avidity of ∼0.54 ± 0.24 μM (Fig. 6A).
This binding was specific as it was blocked by the MNoV neu-
tralizing antibody A6.2.1 (Fig. 6B) (2).
To assess the role of P domain contacts with CD300lf seen in
the cocrystal structures (Figs. 1 and 6D), variant P domains were
tested for their ability to bind Fc–CD300lf using BLI pins coated
with biotin-labeled CW1 P domain or variants dipped into wells
containing 5 μM Fc–CD300lf. The MNoV strain CW3 P domain
was also tested. It differs by a single amino acid from CW1,
having a lysine instead of a glutamic acid at position 296 (4).
CW3 binds A6.2.1 similarly to CW1 (34) and also binds well to Fc–
CD300lf (Fig. 6C). In contrast, CD300lf binding was undetectable
after deletion of three amino acids from the P domain DE loop
(Asn364, Ala365, and Asp366). The DE loop variant also failed to
bind monomeric CD300lf in the ITC binding assay (SI Appendix,
Fig. S5), although it appears folded because it is recognized by
A6.2.1, which is reported to not recognize denatured VP1 by im-
munoblot (2). Similarly, substitution of four residues in the AB loop
region (Q298R, S299E, G300P, and V304K) diminished Fc–
CD300lf binding to near background. Likewise, the substitution of
two residues in the P domain E strand (F375D and S377K) also
diminished CD300lf binding. Although the last two variants do not
bind A6.2.1 as well as the wild-type P domain, they migrate similarly
on size exclusion chromatography. The impaired ability to bind
A6.2.1 is likely an effect of the AB loop and E strand mutations on
the A6.2.1 epitope (SI Appendix, Fig. S6). This P domain mutational
analysis clearly provides support for the structurally defined
CD300lf binding determinants.
CD300lf Recognizes Lysates from MNoVCW3-Infected Cells. To ensure
the Fc–CD300lf fusion protein could recognize nonrecombinant
P domain, we tested it against proteins produced in CW3-
infected BV2 cells using an SPR binding assay (Fig. 6E). P do-
main proteins were captured from infected cell lysate on a chip
coated with A6.2.1 antibody, then various concentrations of Fc–
CD300lf were passed over the surface to observe binding. The Fc–
cD300lf bound with an apparent avidity of 0.66 ± 0.56 μM, similar
to that observed for recombinant protein (Fig. 6A). Fc–CD300lf
binding to infected cell lysate was also inhibited by pretreatment
with A6.2.1 antibody, and no binding of A6.2.1 or Fc–CD300lf was
observed for mock-infected cell lysate (SI Appendix, Fig. S7).
These data further support the validity of our quantitative assays
for evaluating CD300lf interactions with viral P domains.
Discussion
The norovirus capsid protein VP1 contains determinants of ge-
nome encapsulation and particle assembly as well as membrane
penetration and entry, thereby representing a portion of the
molecular machinery required for infection. Here we have
structurally defined the interaction between the MNoV P do-
main and the newly discovered entry receptor CD300lf, an in-
teraction that appears to require interfacial coordination of
metal ions. Further, we herein identify bile acids as cofactors for
MNoV infection and establish the P domain structural deter-
minants used in the engagement of the bile acids GCDCA and
LCA. These results are supported by a series of biophysical as-
says that have incorporated analysis of structure-based muta-
tions. These structural and functional studies have significant
implications for our understanding of norovirus biology.
Interactions Between the P Domain and Its Cellular Receptor CD300lf.
Because of its position on the outer face of the viral capsid and
its targeting by neutralizing antibodies (18–23, 29, 34, 35), the
P2 subdomain was a prime candidate for CD300lf receptor en-
gagement. Consistent with this, we show that CD300lf contacts a
cleft in P2 formed by the AB and DE loops, with two receptors
splayed away from the P domain dimer interface (Fig. 1). Feline
calicivirus (FCV) and Hom-1 calicivirus employ junctional ad-
hesion molecule A (JAM-A) and related proteins as receptors
(36, 37). The cryo-EM structure of the FCV capsid in complex
with the two Ig-like extracellular domains of fJAM-A indicates
this receptor also binds to the P2 subdomain, although the re-
ceptors appear to engage the top of the P domain near the dimer
interface (38). This same dimer interface proximal region of P2 is
used by some human noroviruses to bind HBGA glycans (25, 28,
39, 40). Our structural data are robustly supported by quantita-
tive binding analysis (SPR, BLI, and ITC), where mutation of
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critical determinants in the CD300lf CRD3 and CC′ loops along
with mutations in the P domain AB loop, DE loop, and E strand
all result in disruption of the interactions.
CD300lf binding to the P domain of MNoV was potently
blocked using the neutralizing antibody A6.2.1. Cryo-EM models
suggest that A6.2.1 binding site spans both the AB and EF loops
of P2, a conclusion supported by both escape mutants and site-
directed mutagenesis studies (21, 26, 34, 41). This predicts that
the A6.2.1 contact site overlaps with the CD300lf contact site on
the P domain seen in our cocomplex structure (SI Appendix, Fig.
S6), strongly supporting the concept that A6.2.1 inhibits MNoV
infection by blocking cell attachment. The monoclonal antibody
2D3.7 broadly neutralizes MNoV strains and by cryo-EM binds
very close to the A6.2.1 site although at an angle that allows it to
make more contact with the AB and EF loops (21). Based on our
structural studies it seems likely that 2D3.7 also neutralizes
MNoV by blocking the CD300lf binding site.
The Role of Multivalency in Cellular Attachment. The MNoV P do-
main buries ∼630 Å2 of solvent accessible surface at the CD300lf
contact interface, an area notably smaller than that buried in
many other receptor–virus interfaces. For instance, the contact
area buried by HIV gp120 and its receptor CD4 is ∼742 Å2 (42),
between rhinovirus HRV14 and its receptor ICAM‐1 is ∼990 Å2
(43), between coxsackievirus A21 and its receptor ICAM-1 is
∼970 Å2 (44), and between poliovirus and the poliovirus re-
ceptor CD155 is ∼1,300 Å2 (45). Consistent with this small
contact area, the affinity between the P domain and CD300lf is
relatively weak with a KD of ∼25 μM for monotypic binding as
measured in solution by ITC. The low-affinity binding observed
between the P domain and CD300lf suggests that cell attachment
might be avidity-driven, requiring that P domains on a virion
simultaneously engage multiple CD300lf proteins on the cell
surface. We therefore docked the X-ray structure of the complex
onto a cryo-EM–derived model of the MNoV particle. We found
that CD300lf domains cluster in threes on the virion surface (Fig.
7A). The distribution of CD300lf contacts can be seen by re-
moving the CD300lf molecules from the model (Fig. 7B). This
distribution makes clear that each CD300lf cluster is com-
posed of receptors from three different P domain dimers (Fig.
7C). This docking model results in some minor overlap of
CD300 domains (Fig. 7C), which may be resolved by mobility of
P domains, which are flexibly connected to the shell domain
of VP1. These results support a model in which multiple CD300lf
engagements can be made by each virion to drive MNoV binding
and entry. We undertook several binding studies using an Fc–
CD300lf fusion protein, revealing that the bivalent reagent can
bind recombinant P domain and MNoV from infected cell lysates
with an avidity at least 50-fold higher than the monotypic binding
affinities we observed. Because our data are most consistent with a
need for multivalent interactions between the P domain and sev-
eral cell surface CD300lf receptors, the strength of these bivalent
interactions may be physiologically relevant.
Molecular Mimicry by MNoV in Receptor Engagement. Our structure
of CD300lf in complex with phosphocholine has defined the host
ligand binding site used by the receptor. The ligand head group is
orientated so that the fatty acid tail would extend out of the
pocket away from the CD300lf-bearing cell surface, consistent
with the function of CD300lf as a lipid receptor. The ligand
orientation and metal coordination are very similar to that used by
TIM-4, a related immune regulatory molecule, to bind phosphati-
dylserine (SI Appendix, Fig. S8) (46). By comparing the structures
CD300lf bound to either phosphocholine or the MNoV P domain,
we have revealed in precise atomic detail how the viral capsid
mimics binding of a CD300lf ligand and the role of divalent cations
in both of these processes. This form of molecular mimicry predicts
that the interaction between the P domain and CD300lf during
infection would be incompatible with simultaneous binding of li-
gands to the lipid-binding pocket of CD300lf, suggesting that in-
fection might be regulated by high-affinity receptor ligands.
Bacterial ligands may also bind to CD300 family members (10),
raising the possibility that interactions between bacteria and the
Fig. 6. CD300lf binding is inhibited by neutralizing monoclonal antibody
A6.2.1 and involves residues in the P2 subdomain DE and AB loops. Ran-
domly biotin-labeled recombinant MNoV P domain was loaded onto strep-
tavidin biosensors for BLI analysis. The pins were submerged in various
concentrations of Fc-CD300lf to produce the binding curves shown (A).
Analysis yielded a KD apparent = 0.54 ± 0.24 μM representing the mean ± SD
from three independent experiments. The equilibrium concentration curves
were fitted at steady-state assuming a 1:1 binding model. (B) Biosensor pins
loaded with P domain or influenza HA control protein (Materials and
Methods) were placed in A6.2.1 antibody or buffer. After equilibration
against buffer alone, the pins were placed in wells containing Fc-CD300lf.
A6.2.1 (magenta) inhibited binding of Fc-CD300lf compared with pins that
had not been blocked but instead held in buffer (green). No binding was
seen to the control HA-coated pins (black and gray). (C) P domain variants
were assayed by BLI for Fc-CD300lf binding as in B. Streptavidin-coated pins
loaded with biotin-labeled P domain, or P domain variants, were placed in
wells containing 5 μM Fc-CD300lf or A6.2.1 antibody. The responses are
reported as percentage of binding obtained with CW1 strain P domain.
CD300lf binding was undetectable after deletion of the DE loop (Asn364,
Ala365, and Asp368). (D) Position of variant residue alterations, color coded
as in C, and with contacts mapped onto the CD300lf surface. The ribbon
diagram shows the P domain in green with key side chains colored corre-
sponding to the different variants. (E) CD300lf recognizes P domain protein
produced in MNoVCW3-infected cells. The A6.2.1 antibody was immobilized
onto a CM5 chip and used to capture P domain from infected cell lysates.
Various concentrations of Fc-CD300lf were passed over the surface, and the
SPR binding data were analyzed to obtain a KD apparent = 0.66 ± 0.56 μM, as
the mean ± SD from three independent experiments.
































virus may involve binding of ligands to CD300lf that in turn com-
pete for interactions with the P domain.
The Role of Bile in MNoV Infection. We previously showed that
efficient MNoV binding to cells and infection requires a small
molecular weight heat stable serum cofactor (5). Here we show
that the bile acid GCDCA can serve as a cofactor by increasing
cell binding and infection. We do not know if GCDCA is re-
sponsible for the activity originally observed in serum. The role
for this bile acid is likely to involve direct binding to the viral
capsid protein because our crystal structures of the CD300lf–P
domain complex bound with both GCDCA and LCA revealed
two binding pockets per P domain dimer that can accommodate
these bile acids. The location of the bile acid pocket was surprising
for several reasons. First, the bile acid pocket is remote from the
CD300lf–P domain interface, suggesting that if bile acids function by
altering the CD300lf–P domain interaction, this must be via a long-
distance allosteric effect. Second, the bile acid pocket is distinct
from the glycan-binding sites observed on human and murine nor-
ovirus P domains (25, 40), suggesting that norovirus P domains are
promiscuous in their ability to bind diverse biologic small molecules
and further arguing that the interaction between noroviruses and
target cells is regulated at multiple levels. It seems likely that the
efficiency of norovirus infection of cells in culture requires that each
of these different levels of control be perfectly matched to avoid
abortive infection. Third, binding of GCDCA and LCA to MNoV P
domain did not induce significant structural rearrangements in the P
domain or in the CD300lf interface. We did find that addition of
GCDCA had a small (approximately twofold) but reproducible ef-
fect on binding of soluble CD300lf to the P domain in the presence
of divalent cations. It is possible that this small effect, summed over
the many copies of the P domain on the virion, has biological sig-
nificance. However, this is speculative, and the molecular mecha-
nism of cofactor function remains an open question. It is intriguing
to consider that bile acids, rather than directly modulating receptor:
P domain interactions, instead alter the structural conversions that
occur as the virus enters the cell to release its RNA into the cyto-
plasm or the conformation of the virion itself in ways not detected
by biding studies of the P domain and CD300lf in solution.
We also found that addition of calcium and magnesium also
augments infection. Our structural data indicate that there are
at least three divalent cation binding sites associated with
CD300lf binding to each P domain monomer. Two of these are
in the binding interface between the P domain and CD300lf
and likely facilitate the interaction. A third metal ion is lo-
cated midway between the receptor and bile acid binding sites
of the P domain, directly participating in neither interaction.
Crystal structures and ITC binding of the MNoV P domain
with CD300lf showed that either magnesium or calcium can
support complex formation. Of particular interest, Ca2+ is
present in high concentrations in bile (47), making it reason-
able to propose that calcium might be present at sites of
MNoV infection (48). It is intriguing to speculate that the
availability of divalent cations in the body, which may not be
available in the environment, might foster infectivity of the
virus once it reaches its target.
Implications of These Studies. These studies support the concept
that noroviruses have evolved to be dependent on small mole-
cules either by molecular mimicry of host lipids or by depending
on cofactors such as bile acids and divalent cations for critical
steps in infection. Physiologically, it is attractive to consider that
the presence of bile acids and Ca2+ in the intestine downstream
of the common bile duct, in combination with tropism of the
virus for tuft cells as the sole epithelial cell expressing CD300lf
(7), explains the tropism of the virus. This adds to the prior
finding that tuft cell tropism is conferred by the combinatorial
effects of the host cytokine IFNλ and the MNoV nonstructural
protein NS1 (49). Further, although we could not reproducibly
observe an effect of addition of LCA on binding or infectivity
due to solubility issues, this secondary bile acid can also bind to
the MNoV P domain in the pocket used by GCDCA. This in-
dicates that secondary bile acids might serve a physiologically
important role in vivo. However, enhancement appears to be
rather specific because multiple other bile acids did not augment
infection. Because we have not exhaustively sampled primary
and secondary bile acids in the intestine, it is quite possible that
additional cofactors or even inhibitors of norovirus infection will
be discovered in the future.
In addition to identifying that the norovirus P domain interacts
with a soluble cofactor, the structural studies presented here
raise the possibility of designing effective orally bioavailable bile
acid analogs for the treatment of human norovirus infection,
which has also been shown to be enhanced by bile (30). Further,
we previously showed that intestinal bacteria play a critical role
in the establishment of persistent enteric MNoV infection (50).
Because intestinal bacteria are involved in metabolizing primary
bile acids into secondary bile acids, this raises the possibility that
transkingdom interactions between norovirus and enteric bac-
teria are via alterations in bile acids in the intestine. Indeed,
broad-spectrum antibiotics might alter norovirus infection via
alterations in bile acid metabolism (50, 51).
Materials and Methods
Protein Expression and Purification. A cDNA encoding the VP1 P domain of
MNV1 strain CW3 (residues 229 through 540 of GenBank Sequence
ABJ98944.1) was inserted into pET21 between the NdeI and XhoI sites to
create a C-terminal 6His-tag. The P domain of MNV1 clone CW3, which
differs from CW1 by a single amino acid substitution at E296K (which is not
present at the interface between CD300lf and the P domain), proved more
stable and was used for binding and structural studies except where in-
dicated. The P domain was expressed as a soluble protein in BL21(DE3) cells
(0.2 mM IPTG for 12 h at 25 °C). Cells were lysed in 50 mM Tris·HCl, pH 7.5,
500 mM sodium chloride, 10% glycerol. The supernatant was incubated on
Ni-NTA agarose, washed, and protein eluted in 2× PBS at pH 8.0 containing
Fig. 7. Docking of CD300lf–P domain complex onto a cryo-EM–derived model
of theMNoV virion. (A) The solvent accessible surfaces of CD300lf are shown in
yellow, with the P domain subunits in blue and green. The CD300lf domains
group in threes across the surface of the virion. Each CD300lf trimer is made up
of receptors from three different P domain dimers. (B) The CD300lf contacts
mapped in yellow on the model surface after removing CD300lf. Fivefold,
threefold, and twofold symmetry is marked with a white pentagram, triangle,
or ellipse, respectively. (C) (Right) A top-down view (same orientation as in A)
for three P dimers in a trimer cluster with the shell region below in blue. (Left)
A side view of the three P dimers. Note how the CD300lf C termini (marked by
red cylinders) cluster at the center of each trimer and overlap slightly. The
magenta ovals with a white letter B mark visible bile acid binding pockets.
E9208 | www.pnas.org/cgi/doi/10.1073/pnas.1805797115 Nelson et al.
300 mM Imidazole. The P domain was purified over a Superdex column and
was found to be monomeric (SI Appendix, Fig. S9). The CD300lf expression
construct encodes residues 19–131 of NP_663609.2 inserted between the
NdeI and XhoI sites of pET21. In brief, CD300lf protein was recovered from
BL21(DE3) inclusion bodies, denatured in guanidine hydrochloride, and then
oxidatively refolded by rapid dilution following standard methods (52).
Refolded protein was purified over Superdex S200 and confirmed to be
monomeric. The Fc–CD300lf construct hinge region was designed to be too
short to allow both CD300lf domains to bind simultaneously to both sites on
a P domain dimer. The construct joins residues 20–128 of NP_663609.2 with
the Fc portion of human IgG2 in a pCDNA3.1 expression vector using an
IL-2 signal peptide. The amino acid sequence of the Fc hinge region starts
ASVECPPCP. The fusion protein was produced in HEK293 cells and purified
on protein G followed by Superdex 200 gel filtration.
Crystallization and Structure Determination. Cocomplexes were made by
mixing equal molar amounts of MNV1.CW3 P domain with murine CD300lf in
25 mM Tris·HCl, pH 7.4, 150 mMNaCl. The mix was concentrated to 15 mg/mL
and buffered exchanged to 20 mM Tris·HCl, pH 8.7, containing 20 mM NaCl.
Crystals grew in hanging drops at 20 °C in 0.1 M Tris·HCl, pH 8.7, 0.1 MMgCl2,
and 10% (wt/vol) PEG 8000. They were soaked in well solution containing
20% (vol/vol) ethylene glycol then flash-cooled in liquid nitrogen for data
collection. The LCA containing CD300lf–P domain complex crystals were
grown in 100 mM Tris·HCl, pH 8.7, 40 mM CaCl2, and 5.5% PEG 10,000.
Because LCA is only slightly soluble in water, a drop of ethanol containing
0.1 μg of LCA was placed on the coverslip and allowed to air dry before the
protein and mother liquor were added. Crystals were prepared for freezing
by adjusting the concentration of PEG 10,000 in the drop to 25%. Similarly,
the GCDCA crystals were grown in 100 mM Tris·HCl, pH 8.7, 110 mM MgCl2,
and 11.0% PEG 10,000 with 0.1 mM GCDCA. These crystals were soaked in
well buffer containing 15% (vol/vol) ethylene glycol and then flash-cooled in
liquid nitrogen for data collection. CD300lf–phosphocholine crystals were
grown in 33% (wt/vol) PEG 3350 using 100 mM phosphorylcholine chloride
calcium salt adjusted to pH 7.4. Data were collected at 100°K on the Ad-
vanced Light Source (ALS) 4.2.2 beamline and processed with XDS (53). Initial
phases were determined by molecular replacement using Phaser (54) with
models from mouse CD300lf (PDB ID code 5FFL) and P domain (PDB ID code
3LQE) (26). Refinement was carried out in Phenix (55), with manual re-
building in Coot (56). Data collection and refinement statistics are summa-
rized in SI Appendix, Tables S1 and S2. The final coordinates were assessed
using MolProbity (57). Solvent accessible area calculations used Naccess (58).
Interface contacts were identified using the PISA server (59). Structure fig-
ures were rendered with PyMOL (60).
Virus Purification from Infected Cells. BV2 cells grown to a density of 45 × 106
cells per 100 mL were infected with MNV1.CW3 (MOI of 0.05) and virus re-
covered 36 h later. Virus-infected cells were lysed by freezing at −80 °C and the
lysate concentrated 10-fold over a 100-kDa membrane. After filtration (0.45
μm), 23 mL of concentrated lysate was pelleted through a 5-mL layer of 30%
sucrose in 1× PBS for 3 h at 100,000 × g. The virus pellet was resuspended in
250 uL of PBS. A mock lysate was prepared from uninfected BV2 cells.
Surface Plasmon Resonance Binding Analysis. Recombinant neutravidin was
immobilized on a CM5 chip in 10 mM sodium acetate, pH 3.5, by standard
amine coupling. Proteins were captured by random biotin labeling. Briefly,
100 μg of protein was mixed with biotin (EZ-Link-NHS-PEG4-Biotin; Thermo
Fisher) at a molar ratio of 20:1 biotin:protein and incubated. Unreacted bi-
otin was removed with a desalting column (Zeba Spin 7K; Thermo Fisher).
The control lane was coated with biotin-labeled hemagglutinin (HA) extra-
cellular domain from influenza A virus subtype H5N1 (A/Indonesia/5/2005).
The HA control protein has an isoelectric point similar to the P domain of
MNV1 and was made using baculovirus-infected High Five cells. The test lane
contained biotin-labeled P domain. Both control and test lanes contained
∼3,000 RU of biotin-labeled protein. The binding buffer was 100 mM Sodium
Phosphate (pH 7.4), 400 mM NaCl, 40 μM EDTA, and 0.005% (vol/vol) Tween-
20 to minimize background. Monomeric CD300 family ectodomains were
tested at 200 μM at a flow rate of 30 μL/min. The high protein concentrations
required to show binding gave rise to higher than normal responses on the
control lane, often approaching 60% of the total signal. We subtracted the
HA control lane response from the P domain test lane response to obtain
the specific binding. In the infected cell lysate assay, the antibody A6.2.1 was
immobilized onto CM5 in 10 mM sodium acetate, pH 3.5, by standard amine
coupling. CW3-infected BV2 cell lysate was passed over the chip in binding
buffer consisting of PBS (pH 7.4) and 0.005% (vol/vol) Tween-20. P domain
was detected by passing concentrations of Fc–CD300lf over the captured
material. For the reference surface, chikungunya virus-specific antibody
CHK-265 was immobilized onto the chip and used to capture recombinant
chikungunya virus-like particles produced as described (61). We subtracted
the CHK-265 control lane response from the infected cell lysate test lane
response to obtain the specific binding. The saturation value was arbitrarily
taken as 300 s after start of the injection (not equilibrium) and used to
calculate the KD apparent by fitting to a 1:1 binding model. SPR experiments
were performed using a Biacore T200 (GE Healthcare) at 25 °C.
Biolayer Interferometry Binding Analysis. The apparent binding affinity of Fc–
CD300lf was measured by BLI using an Octet-Red96 device (Pall ForteBio).
Biotin-labeled P domain was loaded onto streptavidin biosensors until sat-
uration, typically 10 μg/mL for 2 min in PBS (pH 7.4) and 0.005% (vol/vol) Tween-
20. Association and dissociationweremeasured at 25 °C. The real-time data were
analyzed using Biaevaluation 3.1. Steady-state equilibrium concentration curves
were fitted using a 1:1 binding model to obtain an apparent KD (avidity).
Negative control, streptavidin biosensors were loaded with biotin-labeled
H5N1 influenza protein. For comparison, the binding of each P domain variant
was normalized to the amount of binding by the CW1 wild-type P domain.
Isothermal Titration Calorimetry. Titration calorimetry was performed with
a VP-ITC calorimeter (Microcal). Proteins were dialyzed overnight against
buffer containing 30 mM Hepes, pH 7.4, 150 mM NaCl with 1 mM CaCl2. For
some experiments the CaCl2 was replaced with 0.1 mM EGTA, or 0.1 mM
EGTA and MgCl2 as indicated. Aliquots of the CD300lf solution were added
by means of a 270-μL rotating stirrer-syringe (at 134 rpm) to a cell, con-
taining 1.4 mL of the P domain solution. The concentration of P domain or
CD300lf used is given under the titration plots (SI Appendix, Figs. S4 and S5).
P domain concentrations ranged from 50 to 294 μM, whereas CD300lf con-
centrations varied from 900 to 3,694 μM. The heat of dilution was found
negligible in separate titrations of CD300lf into the buffer solution. The heat
of reaction was obtained by integration of each peak obtained after in-
jection of titrant. All titrations were performed at 25 °C. Calorimetric data
was analyzed with ORIGIN 7.0 software. Binding parameters such as the
number of binding sites (n), the binding constant (K, M−1), and the binding
enthalpy (ΔH, kcal/mol of bound ligand) were determined by fitting the
experimental binding isotherms to a one-site binding model. All parameters
were allowed to float during the least-squares minimization process. The
GCDCA bindings to P domain titrations were done with bile acid in the syringe
dissolved in the ITC buffer used to dialyze the P domain protein. The buffer
consisted of 30 mMHepes, pH 7.4, 150 mM NaCl with 1 mM CaCl2. The GCDCA
concentration in the syringe ranged from 1,000 to 2,500 μM, and P domain
concentrations in the well were between 63 and 100 μM. The GCDCA data
were fitted to a one-site binding model. The heat of dilution was determined
to be negligible in separate titrations of GCDCA into the buffer solution. The
calculated binding stoichiometries (n) for both CD300lf and GCDCA on the P
domain were close to unity, consistent with the structural data showing two
CD300lf and two GCDCA binding sites per P domain dimer. The data curve fits
indicate that binding of GCDCA to the recombinant P domain could be more
complex than a simple one-site model, for example, monomer/dimer equlibria.
MNoV Binding Assay. MNoV binding to the surface of BV2 cells was performed as
described (5). Briefly, MNoVwas mixed with BV2 cells on ice in the presence of PBS
in the absence of divalent cations (PBS−/−) and either 10% FBS, 0.025%W/V bovine
bile, 500 μM sodium glycochenodeoxycholic acid (GCDCA), 500 μM taurocholic
acid (TCA), or 0.07%W/V casein. Unbound virus was washed off after 30 min, and
then the ratio of viral genomes to host actin was determined by qPCR.
MNoV Infection Assay. Two million BV2 cells were plated per well in a six-well
plate for culture overnight in DMEM containing 10% FBS to produce a
confluent monolayer as described (5). The cells were washed with PBS and
the medium replaced with PBS−/− containing either 10% FBS, 0.9 mM calcium and
0.5 mM magnesium (PBS+/+), 500 μM of various bile acids, or 0.5 μg/mL histo-
blood group antigen HBGA. One thousand plaque-forming units (PFUs) of
MNVCW3 were adsorbed at room temperature for 30 min in the presence of
cations, bile acids, or HBGA as indicated. Unbound virus was then washed
off, and a methycellulose overlay containing 10% FBS was applied to allow
for quantification of PFUs 48 h postinfection. PFUs were determined by
staining with crystal violet (5). Each experiment was performed at least in
duplicate in three independent experiments. In each experiment, PFUs for a
given condition were normalized to that of the 10% FBS condition.
Docking the Cocomplex Structure on theMNoV Virion. Themodel forMNV-1/CD300lf
complex was derived from the pseudoatomic model of MNV-1 as previously
described (17, 62). Briefly, the atomic structures of the MNV-1 P domain (26) and
































the rNV shell domain (16) were fitted into the 8 Å MNV-1 image reconstruction
density (17) and refined using Situs (63). To facilitate generation of the entire
capsid, the cryo-EM map was first rotated from the EMAN2 (64) to the Virus
Particle Explorer (VIPER) (65) convention for icosahedral orientation and an
icosahedral protomer unit of A, B, and C subunits were built into the density. The
atomic structure of the P domain/CD300lf complex was then fitted onto the A/B
and C/C P domain dimers using Coot (56). The new hybrid protomeric unit was
then expanded using VIPER (65).
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